Roche Diagnostics Corporation Sustainability Profile
Roche Diagnostics Corporation, a subsidiary of the Swiss multinational Roche Holding AG, is a leading player in the global healthcare industry, headquartered in the United States. Established in 1896, Roche has consistently innovated in diagnostics, focusing on areas such as molecular diagnostics, tissue diagnostics, and point-of-care testing. With a strong presence in North America, Europe, and Asia, Roche Diagnostics is renowned for its cutting-edge products, including the cobas® series of diagnostic systems and the Elecsys® immunoassay platform. These offerings are distinguished by their accuracy, speed, and ability to deliver comprehensive results, making them invaluable in clinical settings. Roche Diagnostics holds a prominent market position, recognised for its commitment to advancing personalised healthcare and achieving significant milestones in diagnostic technology.
DitchCarbon Score
How does Roche Diagnostics Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Roche Diagnostics Corporation's score of 83 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Roche Diagnostics Corporation, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which influences its climate commitments and emissions reporting. Roche Holding AG has set ambitious climate targets, which are cascaded down to Roche Diagnostics Corporation. These include commitments to reduce greenhouse gas emissions in line with science-based targets, although specific reduction targets for Roche Diagnostics Corporation are not detailed. The parent company is actively involved in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which guide its sustainability efforts. As of now, Roche Diagnostics Corporation has not publicly disclosed any specific emissions figures or reduction initiatives. However, the overarching commitment from Roche Holding AG indicates a focus on sustainability and climate action, aligning with industry standards for reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 403,136,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 188,924,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Roche Diagnostics Corporation's Industry?
How Carbon Intensive is Roche Diagnostics Corporation's Location?
Roche Diagnostics Corporation's Scope 3 Categories Breakdown
Roche Diagnostics Corporation's Scope 3 emissions, which decreased by 8% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 71% of Scope 3 emissions.
Top Scope 3 Categories
Roche Diagnostics Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Roche Diagnostics Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
